Geode Capital Management LLC Raises Holdings in Pro-Dex, Inc. (NASDAQ:PDEX)

Geode Capital Management LLC grew its position in Pro-Dex, Inc. (NASDAQ:PDEX) by 9.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27,435 shares of the medical instruments supplier’s stock after buying an additional 2,296 shares during the quarter. Geode Capital Management LLC’s holdings in Pro-Dex were worth $819,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Dimensional Fund Advisors LP lifted its holdings in shares of Pro-Dex by 5.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock worth $1,238,000 after buying an additional 3,067 shares during the period. Bard Associates Inc. lifted its holdings in shares of Pro-Dex by 17.6% in the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock worth $406,000 after buying an additional 2,031 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Pro-Dex by 7.9% in the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock worth $240,000 after buying an additional 900 shares during the period. Finally, FMR LLC lifted its holdings in shares of Pro-Dex by 34.9% in the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock worth $119,000 after buying an additional 1,028 shares during the period. 15.28% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO Alisha Charlton sold 1,000 shares of the company’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $40.02, for a total transaction of $40,020.00. Following the transaction, the chief financial officer now directly owns 15,339 shares of the company’s stock, valued at $613,866.78. This represents a 6.12 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 47.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Ascendiant Capital Markets upped their target price on Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a report on Monday, November 11th. StockNews.com upgraded Pro-Dex from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 14th.

Pro-Dex Trading Down 5.5 %

Shares of NASDAQ PDEX opened at $46.97 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.41 and a quick ratio of 1.94. The stock has a market capitalization of $153.08 million, a P/E ratio of 30.50 and a beta of 0.56. Pro-Dex, Inc. has a 1-year low of $16.18 and a 1-year high of $59.60. The business has a fifty day moving average price of $47.92 and a 200 day moving average price of $31.93.

Pro-Dex Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.